The comparison of efficacy and safety of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia and schizoaffective disorder

Trial Profile

The comparison of efficacy and safety of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia and schizoaffective disorder

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2006

At a glance

  • Drugs Olanzapine; Quetiapine
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Oct 2006 The expected completion date for this trial is now .
    • 27 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top